Advanced

Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries

Milsom, Ian; Axelsen, Susanne; Kulseng-Hansen, Sigurd; Mattiasson, Anders LU ; Nilsson, Carl Gustaf and Wickstrom, Jannie (2009) In Acta Obstetricia et Gynecologica Scandinavica 88(6). p.693-699
Abstract
Objective. The purpose of the present analysis was to analyze and compare the cost-effectiveness of solifenacin flexible dosing (5-10 mg) with tolterodine 4 mg sustained release (SR) or placebo (assumed to be comparable to no treatment) for patients with overactive bladder (OAB) symptoms. Design. A decision-analytic model was constructed. Methods. Costs and effects were evaluated for the three treatment options in a one-year timeframe. Costs included were treatment costs, cost of pad use, and patients productivity loss based on data from the Nordic countries. Sample. Results from two randomized controlled trials were used as input data in the cost-effectiveness analysis. Main outcome measures. Quality adjusted life years and incremental... (More)
Objective. The purpose of the present analysis was to analyze and compare the cost-effectiveness of solifenacin flexible dosing (5-10 mg) with tolterodine 4 mg sustained release (SR) or placebo (assumed to be comparable to no treatment) for patients with overactive bladder (OAB) symptoms. Design. A decision-analytic model was constructed. Methods. Costs and effects were evaluated for the three treatment options in a one-year timeframe. Costs included were treatment costs, cost of pad use, and patients productivity loss based on data from the Nordic countries. Sample. Results from two randomized controlled trials were used as input data in the cost-effectiveness analysis. Main outcome measures. Quality adjusted life years and incremental cost-effectiveness ratio. Results. Solifenacin flexible dosing was more effective with respect to reducing OAB symptoms compared to both placebo and tolterodine 4 mg. Treatment with both solifenacin and tolterodine was more costly compared to placebo, but treatment with solifenacin was a less costly alternative compared to tolterodine 4 mg SR. Sensitivity analyses revealed that the conclusions were robust. Conclusion. Solifenacin flexible dosing was a cost-effective treatment alternative compared to tolterodine 4 mg SR. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
overactive bladder, solifenacin, Nordic, incontinence, urinary, Cost-effectiveness
in
Acta Obstetricia et Gynecologica Scandinavica
volume
88
issue
6
pages
693 - 699
publisher
Wiley-Blackwell
external identifiers
  • wos:000267201800012
  • scopus:66149123002
ISSN
1600-0412
DOI
10.1080/00016340902849738
language
English
LU publication?
yes
id
ce811421-aae7-4353-bf0c-5c3d041fab67 (old id 1441814)
date added to LUP
2009-07-27 15:11:11
date last changed
2017-02-22 11:44:20
@article{ce811421-aae7-4353-bf0c-5c3d041fab67,
  abstract     = {Objective. The purpose of the present analysis was to analyze and compare the cost-effectiveness of solifenacin flexible dosing (5-10 mg) with tolterodine 4 mg sustained release (SR) or placebo (assumed to be comparable to no treatment) for patients with overactive bladder (OAB) symptoms. Design. A decision-analytic model was constructed. Methods. Costs and effects were evaluated for the three treatment options in a one-year timeframe. Costs included were treatment costs, cost of pad use, and patients productivity loss based on data from the Nordic countries. Sample. Results from two randomized controlled trials were used as input data in the cost-effectiveness analysis. Main outcome measures. Quality adjusted life years and incremental cost-effectiveness ratio. Results. Solifenacin flexible dosing was more effective with respect to reducing OAB symptoms compared to both placebo and tolterodine 4 mg. Treatment with both solifenacin and tolterodine was more costly compared to placebo, but treatment with solifenacin was a less costly alternative compared to tolterodine 4 mg SR. Sensitivity analyses revealed that the conclusions were robust. Conclusion. Solifenacin flexible dosing was a cost-effective treatment alternative compared to tolterodine 4 mg SR.},
  author       = {Milsom, Ian and Axelsen, Susanne and Kulseng-Hansen, Sigurd and Mattiasson, Anders and Nilsson, Carl Gustaf and Wickstrom, Jannie},
  issn         = {1600-0412},
  keyword      = {overactive bladder,solifenacin,Nordic,incontinence,urinary,Cost-effectiveness},
  language     = {eng},
  number       = {6},
  pages        = {693--699},
  publisher    = {Wiley-Blackwell},
  series       = {Acta Obstetricia et Gynecologica Scandinavica},
  title        = {Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries},
  url          = {http://dx.doi.org/10.1080/00016340902849738},
  volume       = {88},
  year         = {2009},
}